A recent Danish nationwide cohort study (2003–2022) published in the Journal of the American Heart Association (JAHA) highlights persistent disparities in the care and outcomes of heart failure vulnerable populations. Despite two decades of medical advancement and a universal healthcare system, patients with mental illness, frailty, or advanced age continue to face significantly higher mortality risks compared to their counterparts.

Disparities in Heart Failure Vulnerable Populations

The study analyzed data from 154,819 patients with new-onset heart failure (HF). The researchers defined eight vulnerable subgroups: individuals aged 80 years or older, women, those with low income, people living alone, patients with mental illness, individuals from non-Western backgrounds, frail patients, and rural residents. While the overall five-year mortality rate for HF declined between 2003 and 2022, the study found that these benefits were not distributed equally across all demographics.

Notably, the following groups showed concerning trends in mortality:

• Mental Illness: Patients with diagnosed mental illness saw virtually no improvement in mortality rates over the entire 20-year study period.


• Elderly and Frail: Those aged 80 years and above, as well as frail patients, experienced a much smaller decline in mortality compared to younger, non-frail peers.


• Social Isolation: Patients living alone also showed a significantly lesser reduction in all-cause mortality than those with domestic support.

Treatment Gaps and Guideline Compliance

The initiation of guideline-recommended medical therapy (GDMT), including beta-blockers and renin-angiotensin system inhibitors, generally improved across the entire cohort. However, a critical gap remains in the utilization of mineralocorticoid receptor antagonists (MRAs). The research indicates that initiation of MRAs was insufficient among vulnerable patients. This treatment gap likely contributes to the stagnant mortality rates observed in certain high-risk subgroups.

Clinical Implications for the Indian Healthcare Context

In India, the burden of HF is particularly heavy due to the younger age of onset, often appearing ten years earlier than in Western populations. Findings from the INTER-CHF study show that heart failure patients in India have one of the highest one-year mortality rates globally, at approximately 23%. Challenges such as low insurance coverage, limited access to specialist care in rural areas, and the high cost of long-term medication exacerbate risks for heart failure vulnerable populations. For Indian clinicians, prioritizing aggressive GDMT initiation and addressing social determinants like financial strain and domestic support are vital for improving long-term survival.

Frequently Asked Questions

Which groups are specifically considered vulnerable in heart failure management?

In this study, vulnerable groups included the elderly (80+), frail individuals, those living alone, patients with mental illness, low-income earners, rural residents, and non-Western ethnic groups. These factors often overlap, creating complex barriers to care.

Why did mortality not improve for patients with mental illness?

Factors such as reduced treatment adherence, potential interactions between psychiatric and cardiac medications, and social stigma may prevent these patients from receiving the same quality of cardiovascular follow-up as others.

What is the most significant treatment gap identified in this study?

The most significant gap was the inadequate initiation of mineralocorticoid receptor antagonists (MRAs) in vulnerable subgroups. While other life-saving medications saw increased uptake, MRAs were underutilized in those who needed them most.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ødum SF et al. Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022. J Am Heart Assoc. 2026 Apr 09. doi: 10.1161/JAHA.125.044072. PMID: 41954059.


2. Dokainish H et al. Global mortality and hospitalisation in heart failure patients (INTER-CHF study): a multinational prospective cohort study. Lancet Glob Health. 2017;5(8):e789-e797.


3. Jeemon P et al. Socio-economic status and financial burden of heart failure management in India: A multi-center prospective study. Global Heart. 2026;21(1):15-28.